404950-80-7
Panobinostat
CAS: 404950-80-7
Molecular Formula: C21H23N3O2
404950-80-7 - Names and Identifiers
404950-80-7 - Physico-chemical Properties
| Molecular Formula | C21H23N3O2 |
| Molar Mass | 349.43 |
| Density | 1.241±0.06 g/cm3(Predicted) |
| Melting Point | 114-117?C |
| Solubility | Soluble in DMSO (70 mg/ml), methanol, water (<1.2 mg/ml), DMF (~50 mg/ml), and ethanol |
| Appearance | solid |
| Color | Off-white |
| pKa | 8.71±0.23(Predicted) |
| Storage Condition | -20°C Freezer, Under Inert Atmosphere |
| Stability | Stable for 1 year from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20° for up to 1 month. |
| Use | An HDAC inhibitor reported to inhibit human multiple myeloma cell lines. |
| In vitro study | LBH589 induced apoptosis in MOLT-4 and Reh cells in a time-and dose-dependent manner. Moreover, LBH589 acted more effectively on MOLT-4 cells than on Reh cells. LBH589 significantly prevented the growth of MOLT-4 and Reh cells for 48 h in a dose-dependent manner. The cells treated with LBH589 had a 2-to 3-fold increase in the number of cells in the G2/M phase of the cell cycle compared to the control cells. LBH589 was associated with acetylation of histones H3K9 and H4K8, and LBH589 also decreased c-Myc expression levels in a dose-dependent manner. LBH589 also enhanced the expression level of p21. The lowest dose of LBH589(10 nM) treatment of Reh cells initially enhanced the expression level of c-Myc and then decreased the expression level of c-Myc. In addition, LBH589 promotes a large increase in pro-apoptotic and DNA repair genes at the mRNA level. Under the action of GADD45G promoter, LBH589 induced an increase in the level of acetylated histones H3 and H4. In addition, LBH589 inhibited the growth of non-small cell lung cancer cell lines, such as human H1299,L55 and A549, with IC50 of 5,11 and 30 nM, respectively; Mesothelioma cell growth, such as human OK-6 and OK -5, The IC50 is 5 and 7 nM, respectively; And small cell lung cancer cell lines, such as human RG-1 and LD-T, The IC50 is 4 and 5 nM, respectively. |
| In vivo study | LBH589 significantly reduced tumor growth in animal models of lung cancer and mesothelioma by an average of 62% compared to controls. The effect of LBH589 on immunocompetent mice is similar to that of severe combined immunodeficiency mice, indicating that LBH589 inhibits tumor growth and has nothing to do with Immunology. LBH589 injected intraperitoneally at a dose of 20 mg/kg for 5 days per week resulted in an average 70% decrease in tumor growth at the end of the experiment. Compared with corresponding control tumors, LBH589 decreased by 53% in H526-derived tumors, 81% in BK-T-derived tumors, and 76% in RG-1-derived tumors, the effect on H69 derived tumors decreased by 70%. Under the same conditions and doses, LBH589 acts on NSCLC and Meso-derived xenografts, resulting in two kinds of decline in SCLC-derived tumors, with BK-T derived mean tumor size from 296 mm at the start of the experiment |
404950-80-7 - Risk and Safety
| Risk Codes | R22 - Harmful if swallowed R36/37/38 - Irritating to eyes, respiratory system and skin. R20 - Harmful by inhalation |
| Safety Description | 24/25 - Avoid contact with skin and eyes. |
| HS Code | 29339900 |
404950-80-7 - Introduction
Panobinostat (LBH589) is a novel, broad-spectrum HDAC inhibitor with an IC50 of 5 nM. Phase 3.
Last Update：2022-10-16 17:30:34
404950-80-7 - Reference Information
| multiple myeloma drug | The US FDA approved Panobinostat, an HDAC inhibitor from Novartis, Switzerland, on 23, the trade name faydak is used in combination with bortezomib and dexamethasone in patients with relapsed multiple myeloma treated with bortezomib and an immunomodulator. Panobinostat is the first FDA-approved HDAC inhibitor for the treatment of multiple myeloma. |
| biological activity | Panobinostat (LBH589, NVP-LBH589) is a novel, broad-spectrum HDAC inhibitor, the IC50 in the cell-free assay was 5 nM. Panobinostat (LBH589) induces autophagy and apoptosis. Panobinostat can effectively disrupt the latency of HIV in the body. Phase 3. |
| Target | Value |
| HDAC (MOLT-4 cells) | 5 nM |
| HDAC (Reh cells) | 20 nM |
Last Update：2024-04-10 22:29:15
Supplier List
Spot supply
Product Name: Panobinostat Visit Supplier Webpage Request for quotationCAS: 404950-80-7
Tel: 0714-3999186
Email: 2853786052@qq.com
Mobile: 86+15671228036
QQ: 2853786052
Wechat: 15671228036
Spot supply
Product Name: Panobinostat (LBH589) Visit Supplier Webpage Request for quotationCAS: 404950-80-7
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
Spot supply
Product Name: Panobinostat Visit Supplier Webpage Request for quotationCAS: 404950-80-7
Tel: 0714-3999186
Email: 2853786052@qq.com
Mobile: 86+15671228036
QQ: 2853786052
Wechat: 15671228036
Spot supply
Product Name: Panobinostat (LBH589) Visit Supplier Webpage Request for quotationCAS: 404950-80-7
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
View History